EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Preparation, Oral SNEDDS Formulation, and In Vivo Evaluation of the HIV-1 Latency-Reversing Agent EK-16A

Lu Jin, Yuqi Zhu, Fan Yang, Ting Chen, Xinyi Yang iD, Yuan Tang, Yipeng Cheng, Dengji Zhang, Jingna Xun iD, Jun Liu, Bin Wang, Chunyu Li iD und 9 weitere

Molecules · 01.06.2026 · 31 (11) · 1897

DOI: 10.3390/molecules31111897 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecules, online erschienen am 01.06.2026. Verfasst von Lu Jin und 20 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Sciences, Fudan University, Shanghai 200438, China. Hauptthemen laut MEDLINE: HIV-1, Diterpenes, Anti-HIV Agents. Die Arbeit nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: AIDS is a serious threat to human health and remains incurable; however, EK-16A, an ingenol derivative, shows promise as a functional cure. In this study, we aimed to extract EK-16A from Euphorbia kansui, used in traditional Chinese medicine, to develop an oral self-nanoemulsifying drug delivery system (SNEDDS) for EK-16A and evaluate it in vivo.

Methods

EK-16A was purified by SFC combined with conventional extraction. The optimal SNEDDS formulation was selected by emulsification and stability testing. Pharmacokinetics, metabolomics, and proteomics were used for in vivo evaluation.

Results

1. The extraction yield of EK-16A was four times higher than that of the conventional process; the extraction scale was increased by 25 times, and the purity of EK-16A reached 98.0%. 2. EK-16A is a BCS Class IV compound with low solubility and permeability. The compound’s content degraded to 49.8% after 3 months at 25 °C/60% RH. The EK-16A SNEDDS formulation A#1 showed no degradation after 3 months at 40 °C/75% RH. The absolute bioavailability after oral administration of formulation A#1 in rats was 0.445%. 3. The proteomics results showed that EK-16A significantly downregulated the PI3K-AKT signaling pathway in SHIV-infected rhesus macaques. Specifically, all 11 identified differential proteins were significantly downregulated.

Conclusions

1. The extraction process for EK-16A features high yield, purity and large scale. 2. The SNEDDS formulation enhances the stability of EK-16A and successfully delivers this low-solubility and permeability compound into the systemic circulation. 3. Proteomics analysis revealed that EK-16A significantly downregulates the PI3K-AKT signaling pathway in SHIV-infected rhesus macaques. However, further experiments, such as measuring plasma viremia and cell-associated SHIV RNA, are needed to confirm this mechanism.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV-1DiterpenesAnti-HIV AgentsAnimalsAdministration, OralRatsMaleEuphorbiaDrug Delivery SystemsHumansEmulsions

Stichwörter der Autor:innen

EK-16AEuphorbia kansuiHIV-1PI3K/AktSNEDDS

Substanzen

DiterpenesEmulsionsAnti-HIV Agents

Autor:innen und Institutionen

  • School of Life Sciences, Fudan University, Shanghai 200438, China.
  • College of Clinical Pharmacy, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China.
  • NHC Key Laboratory of Human Disease Comparative Medicine, National Center of Technology Innovation for Animal Model, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Peking Union Medical C…

ORCID-Profile: Xinyi Yang, Jingna Xun, Chunyu Li, Zhujian Wang, Jing Xue

Förderung

  • National Key Research and Development Program of China

Zitieren

APA

Jin, L., Zhu, Y., Yang, F., Chen, T., Yang, X., Tang, Y., Cheng, Y., Zhang, D., Xun, J., Liu, J., Wang, B., Li, C., Wang, X., Li, S., Yu, X., Wang, Z., Zhang, Y., Zhong, Q., Ma, J., …, & Zhu, H. (2026). Preparation, Oral SNEDDS Formulation, and In Vivo Evaluation of the HIV-1 Latency-Reversing Agent EK-16A. Molecules, 31(11), 1897. https://doi.org/10.3390/molecules31111897

Vancouver

Jin L, Zhu Y, Yang F, Chen T, Yang X, Tang Y, et al. Preparation, Oral SNEDDS Formulation, and In Vivo Evaluation of the HIV-1 Latency-Reversing Agent EK-16A. Molecules. 2026;31(11):1897. doi:10.3390/molecules31111897

BibTeX
@article{Jin2026,
  author = {Jin, Lu and Zhu, Yuqi and Yang, Fan and Chen, Ting and Yang, Xinyi and Tang, Yuan and Cheng, Yipeng and Zhang, Dengji and Xun, Jingna and Liu, Jun and Wang, Bin and Li, Chunyu and Wang, Xingyu and Li, Suixiang and Yu, Xingwen and Wang, Zhujian and Zhang, Yiping and Zhong, Qian and Ma, Jianrong and Xue, Jing and Zhu, Huanzhang},
  title = {Preparation, Oral SNEDDS Formulation, and In Vivo Evaluation of the HIV-1 Latency-Reversing Agent EK-16A},
  journal = {Molecules},
  year = {2026},
  volume = {31},
  number = {11},
  pages = {1897},
  doi = {10.3390/molecules31111897}
}
Kostenlos starten →